Branded and Biosimilar Ophthalmology
Estimated value
—
Awarded value
—
Suppliers
8
Lots
4
Published
24 Nov 2025
Description
Supply of Branded and Biosimilar Ophthalmology to NHS Scotland.
Scope
- Reference
- NP33925
- Commercial tool
- Standalone contract
- Contract dates
This framework includes the option to extend for any number of periods, up to a maximum overall period of thirty six (36) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- Scotland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Logistics | 5 | quality | — |
| — | 95 | price | — |
| Logistcics | 5 | quality | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 4 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 4 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Aflibercept (Eylea®) | £89.8m | cancelled |
| 2 | Aflibercept Biosimilar | £1 | cancelled |
| 3 | Ranibizumab vials and Pre-filled Syringes | £5.1m | cancelled |
| 4 | Faricimab (Vabysmo®) | £51.7m | cancelled |
Award 1· 0 suppliers
Awarded —
Award 2· 1 supplier
Awarded —
Award 3· 5 suppliers
Awarded —
Award 4· 2 suppliers
Awarded —
Total lots
4
Awarded
4
Estimated total
£146.6m
Awarded total
—
Aflibercept (Eylea®)
Start
—
End
—
Estimated
£89.8m
CPV
Aflibercept Biosimilar
Start
—
End
—
Estimated
£1
CPV
Ranibizumab vials and Pre-filled Syringes
Start
—
End
—
Estimated
£5.1m
CPV
Faricimab (Vabysmo®)
Start
—
End
—
Estimated
£51.7m
CPV